Japan-based Kyowa Hakko Kirin is poised to acquire UK-headquartered Orchard Therapeutics plc for a total consideration of USD 477.6 million. The deal comprises USD 387.4 million in cash and USD 90.2 million in Contingent Value Rights (CVRs), with the transaction expected to close in the first quarter of 2024.
Acquisition of Libmeldy to Enhance Rare Disease Portfolio
As part of the acquisition, Kyowa Hakko Kirin will gain access to Orchard’s Libmeldy (atidarsagene autotemcel, OTL-200), a transgenic autologous hematopoietic stem cell (HSC) therapy approved in the European Union for the treatment of metachromatic leukodystrophy (MLD). This rare genetic disorder is characterized by reduced ARSA enzyme activity in children due to biallelic mutations in the ARSA gene. Libmeldy is the first approved treatment for eligible early-onset MLD patients and has received priority review status in the United States, with a PDUFA date set for March 18, 2024.
Expanding Development Pipeline with Additional Therapies
In addition to Libmeldy, Orchard Therapeutics is advancing its pipeline with clinical candidates OTL-203 and OTL-201, which target Mucopolysaccharide Storage Syndrome Type I (Hurler Syndrome, MPS-IH) and Mucopolysaccharide Storage Syndrome Type IIIA (MPS-IIIA), respectively. This acquisition positions Kyowa Hakko Kirin to strengthen its commitment to developing innovative therapies for rare diseases.-Fineline Info & Tech
